SEC Comment Letter for INTEST CORP (INTT) (CIK 0001036262) (INTT) — Nov 17, 2020
INTEST CORP (INTT) (CIK 0001036262)
Date: Nov. 17, 2020 · CIK: 0001036262 · Accession: 0000000000-20-010984
AI Filing Summary & Sentiment
File numbers found in text: 333-250047
Letter
United States securities and exchange commission logo November 16, 2020 Richard N. Regan, Jr. President and Chief Executive Officer inTEST Corporation 804 East Gate Drive, Suite 200 Mt. Laurel, NJ 08054 Re:inTEST Corporation Registration Statement on Form S-3 Filed November 13, 2020 File No. 333-250047 Dear Mr. Regan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Katayun Jaffari, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2020
Richard N. Regan, Jr.
President and Chief Executive Officer
inTEST Corporation
804 East Gate Drive, Suite 200
Mt. Laurel, NJ 08054
Re:inTEST Corporation
Registration Statement on Form S-3
Filed November 13, 2020
File No. 333-250047
Dear Mr. Regan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Katayun Jaffari, Esq.